Skip to main content

Table 1 Clinical characteristics of the patients

From: Clinical endocrinological evaluation of the gonadal axis (testosterone, LH and FSH) in prostate cancer patients switched from a GnRH antagonist to a LHRH agonist

  All patients 3 m group 2 m group 1 m group p-value
n 40 10 10 20  
Age 70.6 ± 7.0 73.4 ± 7.9 72.1 ± 6.9 68.5 ± 6.2 0.147
BW (kg) 64.2 ± 7.9 61.7 ± 6.9 62.0 ± 8.9 66.1 ± 6.8 0.289
Height (cm) 166.6 ± 5.1 166.9 ± 3.4 164.5 ± 6.2 165.9 ± 5.3 0.166
BMI 23.1 ± 2.6 22.1 ± 2.3 22.9 ± 2.9 24.0 ± 2.1 0.295
PSA 12.0 ± 9.9 8.91 ± 7.10 17.6 ± 14.9 10.65 ± 6.84 0.177
GS; n (%)
     6 5 (12)   2 (20) 3 (15)  
     7 22 (55) 7 (70) 4 (40) 11 (55)  
     8 8 (20) 3 (30) 2 (20) 3 (15)  
     9 5 (13)   2 (20) 3 (15)  
TNM classification; n (%)
T1cN0M0 5 (13)   2 (20) 3 (15)  
T2N0M0 22 (55) 8 (80) 4 (40) 10 (50)  
T3N0M0 13 (33) 2 (20) 4 (40) 7 (35)  
D’Amico risk classification; n (%)
low 2 (7)   1 (10) 1 (5)  
intermediate 12 (40) 3 (30) 2 (20) 7 (35)  
poor 16 (53) 7 (70) 7 (70) 12 (60)  
  1. Data are presented as means ± SD unless indicated otherwise
  2. BW body weight; BMI Body Mass Index; PSA prostatic specific antigen; GS Gleason score; SD standard deviation